Tuesday, October 27, 2020 4:26:43 PM
ROTH Capital Healthcare Event - COVID-19 Therapeutics in Development - Oct 28, 2020 – 9:00 AM (ET) / 6:00 AM (PT)
Description
ROTH Capital Partners’ Jonathan Aschoff, Ph.D., Tony Butler, Ph.D., Scott Henry, CFA, Zegbeh Jallah, Ph.D., and Elemer Piros, Ph.D., of our Healthcare & Biotechnology team are hosting a webinar to discuss key therapies in the development to treat COVID disease. Our event takes place on October 28, 2020, starting at 9:00 am (ET). The therapies to be discussed are often overlooked and are beyond those of Gilead, Regeneron or Lilly.
There has been an intense focus on the development of COVID-19 vaccines. Several vaccines may emerge by year-end-2020/early-2021, yet the logistics of mass vaccination remain a concern. Additionally, vaccines may not be 100% effective, mutations could overcome vaccine generated immunity, and some people will opt out of vaccination. While herd immunity is critical to overcoming SARS sequelae, therapies against COVID-19 remain important. Minimizing hospitalization, amelioration of COVID-19 disease, and reducing deaths are important contributors to moving us all back into a society of “mask-less” normalcy.
Our Webinar includes three sessions:
Session 1. 9:00-10:20 am (ET). Immune Modulators to Ameliorate COVID Disease 1
INmune Bio (INMB)
Ampio Pharmaceuticals (AMPE)
Humanigen (HGEN)
aTyr Pharma (LIFE)
Omeros (OMER)
FEATURED Integrated Ventures Files Q3/2024 With Mining Revenues Of $1,983,250 And Positive Earnings Of $0.05 Cents Per Share • May 15, 2024 10:30 AM
Swifty Global Announces Impressive Financial Results for Q1 2024 • DRCR • May 15, 2024 10:25 AM
Branded Legacy Inc. Invites Shareholders to Celebrate Milestones at Open House: Announces Share Buyback and Commitment to Authorized Share Count • BLEG • May 15, 2024 8:30 AM
Alliance Creative Group (ACGX) Releases Q1 2024 Financial and Disclosure Report with an 88% increase in Net Income from Q1 2023 to Q1 2024 • ACGX • May 15, 2024 8:30 AM
Category V Biotech, Inc. Announces Letter of Intent to Acquire Genetic Networks, Expanding into Biotechnology Sector • CATV • May 15, 2024 8:00 AM
POET Announces Design Win and Collaboration with Foxconn Interconnect Technology for High-speed AI Systems • POET • May 14, 2024 10:09 AM